Loading...
XNASRIGL
Market cap286mUSD
Jan 08, Last price  
16.25USD
1D
-4.92%
1Q
6.70%
Jan 2017
-31.72%
Name

Rigel Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:RIGL chart
P/E
—
P/S
2.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-35.88%
Rev. gr., 5y
21.30%
Revenues
117m
-2.79%
4,733,00016,526,00033,473,00012,600,0000750,000125,000,0004,750,0002,250,0007,150,0008,250,00028,895,00020,383,0004,484,00044,509,00059,288,000108,621,000149,236,000120,242,000116,882,000
Net income
-25m
L-59.27%
-56,255,000-45,256,000-37,637,000-74,272,000-132,346,000-111,547,00037,890,000-85,973,000-98,840,000-89,027,000-90,908,000-51,464,000-69,216,000-77,992,000-70,480,000-66,546,000-30,391,000-17,914,000-61,596,000-25,091,000
CFO
-6m
L-92.21%
-38,152,000-35,170,000-35,836,000-52,207,000-103,518,000-102,779,00046,743,000-69,375,000-85,192,000-86,061,000-69,753,000-23,413,000-75,889,000-77,557,000-58,826,000-41,510,000-52,185,0005,878,000-73,758,000-5,743,000
Earnings
Mar 03, 2025

Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
URL
https://www.rigel.com/
IPO date
Nov 29, 2000
Employees
155
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
116,882
-2.79%
120,242
-19.43%
Cost of revenue
31,632
62,021
Unusual Expense (Income)
NOPBT
85,250
58,221
NOPBT Margin
72.94%
48.42%
Operating Taxes
3,023
Tax Rate
5.19%
NOPAT
85,250
55,198
Net income
(25,091)
-59.27%
(61,596)
243.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,049
2,124
BB yield
-4.16%
-0.82%
Debt
Debt current
8,613
1,133
Long-term debt
53,635
42,525
Deferred revenue
Other long-term liabilities
39,944
42,264
Net debt
5,315
(14,548)
Cash flow
Cash from operating activities
(5,743)
(73,758)
CAPEX
(450)
Cash from investing activities
(4,297)
72,777
Cash from financing activities
18,367
6,550
FCF
87,011
64,298
Balance
Cash
56,933
58,206
Long term investments
Excess cash
51,089
52,194
Stockholders' equity
(1,407,367)
(1,382,438)
Invested Capital
1,479,938
1,452,639
ROIC
5.81%
3.82%
ROCE
117.47%
82.93%
EV
Common stock shares outstanding
17,402
172,406
Price
1.45
-3.33%
1.50
-43.40%
Market cap
25,232
-90.24%
258,609
-42.76%
EV
30,547
244,061
EBITDA
86,488
59,219
EV/EBITDA
0.35
4.12
Interest
6,872
3,707
Interest/NOPBT
8.06%
6.37%